Concepedia

Author

Ruvim Izikson

Scientific Consulting Group

Also Known As

R. Izikson, Ruvim Izikson

26

Publications

1.3K

Citations

12

H-Index

16

Concepts

All Affiliations

Scientific Consulting GroupIcahn School of Medicine at Mount SinaiJean Brown ResearchUniversity of Rochester Medical CenterCambridge Information Group
RI

About

Ruvim Izikson is an author at Scientific Consulting Group specializing in influenza vaccines, vaccination, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

402

2

Immunology

4

4

362

3

Public Health

1

1

40

4

Pharmacology

1

1

84

5

Immunodominance

1

1

107

Ruvim Izikson

×

11

Publications

1.1K

Citations

11

H-Index

YearCitations

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

Lisa M. Dunkle, Ruvim Izikson, P. Patriarca,

New England Journal of Medicine

2017

274

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial

John J. Treanor, Hana M. El Sahly, James C. King,

Vaccine

2011

159

Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin

Madhusudan Rajendran, Raffael Nachbagauer, Megan E. Ermler,

mBio

2017

156

Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans

Raffael Nachbagauer, Angela Choi, Ruvim Izikson,

mBio

2016

152

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆

Roger Baxter, P. Patriarca, Kathleen Ensor,

Vaccine

2011

107

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant

John J. Treanor, Brandon Essink, Steven Hull,

Vaccine

2013

84

Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age

Lisa M. Dunkle, Ruvim Izikson, P. Patriarca,

The Journal of Infectious Diseases

2017

51

Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans

Daniel Stadlbauer, Arvind Rajabhathor, Fatima Amanat,

mSphere

2017

44

Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age

Ruvim Izikson, David J. Leffell, S. Allan Bock,

Vaccine

2015

40

Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial

Lisa M. Dunkle, Ruvim Izikson, P. Patriarca,

PEDIATRICS

2018

13

Page 1